AV-101 Phase 2a MDD Study
AV-101 is currently being evaluated in an ongoing Phase 2a monotherapy study for the treatment of MDD, a study being conducted and funded by the U.S. National Institute of Mental Health (NIMH), part of the U.S. National Institutes of Health (NIH). Dr. Carlos Zarate of the NIMH is the Principal Investigator of the study. AV-101's mechanism of action is fundamentally differentiated from all FDA-approved antidepressants and atypical antipsychotics, with potential to further drive a paradigm shift towards a new generation of safer and faster-acting antidepressants. VistaGen's development strategy for AV-101 is focused on establishing it as the primary augmentation option for individuals with MDD with inadequate response to standard antidepressants, displacing adjunctive use of atypical antipsychotics such as aripiprazole in the current depression treatment paradigm. VistaGen currently anticipates completion of this NIMH-sponsored Phase 2a study by end of 2017.
Study Center and Contact
|National Institutes of Health Clinical Center
9000 Rockville Pike
Bethesda, MD 20892
|Carlos A Zarate, M.D.|
For more information about the study, please visit www.clinicaltrials.gov.